90561-76-5

Usage

Uses

Used in Pharmaceutical Industry:
AcetaMide, N-[(4-broMophenyl)Methyl]is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activities. Its unique structure allows it to be a key component in the development of new drugs.
Used in Agrochemical Industry:
AcetaMide, N-[(4-broMophenyl)Methyl]is also utilized in the synthesis of agrochemicals, where it can contribute to the development of new pesticides or other agricultural products, enhancing crop protection and yield.
Used in Anti-Cancer Applications:
AcetaMide, N-[(4-broMophenyl)Methyl]has been studied for its potential as an anti-cancer agent, showing promise in the fight against various types of cancer due to its ability to interact with biological targets and inhibit cancer cell growth.
Used in Anti-Inflammatory Applications:
Due to its potential anti-inflammatory properties, AcetaMide, N-[(4-broMophenyl)Methyl]- is being investigated for use in treating inflammatory conditions, helping to reduce swelling, pain, and other symptoms associated with inflammation.
Used in Neurological Disorder Treatment:
AcetaMide, N-[(4-broMophenyl)Methyl]has demonstrated anticonvulsant and sedative properties, making it a candidate for further research and potential use in the treatment of epilepsy and other neurological disorders, where it could help manage seizures and promote relaxation.
Used in Epilepsy Treatment:
AcetaMide, N-[(4-broMophenyl)Methyl]-'s potential use in epilepsy treatment is particularly noteworthy, as it may offer a new avenue for managing this neurological condition and improving the quality of life for those affected.

Upstream product

• 3959-07-7 4-Bromobenzylamine 
• 75-36-5 acetyl chloride 
• 74-90-8 hydrogen cyanide 
• 586-76-5 4-Bromobenzoic acid 
• 106-38-7 para-bromotoluene 
• 75-05-8 acetonitrile 
• 201230-82-2 carbon monoxide 
• 80-43-3 bis(1-methyl-1-phenylethyl)peroxide 
• 873-75-6 4-bromobenzenemethanol 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 141-78-6 ethyl acetate 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 858011-63-9 N-(4-bromo-benzyl)-phthalamic acid 
• 153171-22-3 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 909281-40-9 N-[4-(phenylamino)benzyl]acetamide 
• 588-46-5 N-(phenylmethyl)acetamide 
• 1235450-93-7 N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)acetamide 
• 769966-70-3 3-[4-(N-acetylaminomethyl)phenyl]-5-iso-butyl-N-tert-butylthiophene-2-sulfonamide 
• 39549-67-2 N-acetyl-4-bromobenzamide 

Relevant academic research and scientific papers

Decarboxylative Ritter-Type Amination by Cooperative Iodine (I/III)─Boron Lewis Acid Catalysis

Recent years have witnessed important progress in synthetic strategies exploiting the reactivity of carbocations via photochemical or electrochemical methods. Yet, most of the developed methods are limited in their scope to certain stabilized positions in molecules. Herein, we report a metal-free system based on the iodine (I/III) catalytic manifold, which gives access to carbenium ion intermediates also on electronically disfavored benzylic positions. The unusually high reactivity of the system stems from a complexation of iodine (III) intermediates with BF3. The synthetic utility of our decarboxylative Ritter-type amination protocol has been demonstrated by the functionalization of benzylic as well as aliphatic carboxylic acids, including late-stage modification of different pharmaceutical molecules. Notably, the amination of ketoprofen was performed on a gram scale. Detailed mechanistic investigations by kinetic analysis and control experiments suggest two mechanistic pathways.

C-H Amination via Electrophotocatalytic Ritter-Type Reaction

A method for C-H bond amination via an electrophotocatalytic Ritter-Type reaction is described. The reaction is catalyzed by a trisaminocyclopropenium (TAC) ion in an electrochemical cell under irradiation. These conditions convert benzylic C-H bonds to acetamides without the use of a stoichiometric chemical oxidant. A range of functionality is shown to be compatible with this transformation, and several complex substrates are demonstrated.

N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure–activity relationships and X-ray crystallographic studies

USP7 as a deubiquitinase plays important roles in regulating the stability of some oncoproteins including MDM2 and DNMT1, and thus represents a potential anticancer target. Through comparative analysis of USP7 co-crystal structures in complex with the rep

An unexpected copper-catalyzed carbonylative acetylation of amines

A novel copper-catalyzed carbonylative acetylation of amines has been developed. With peroxide as the oxidant as well as the methyl source with a copper catalyst under CO pressure, good yields of N-acetyl amides could be obtained. Notably, this is the first example of carbonylative acetylation.

Transition-Metal- and Halogen-Free Oxidation of Benzylic sp 3 C-H Bonds to Carbonyl Groups Using Potassium Persulfate

Aryl carbonyl compounds including acetophenones, benzophenones, imides, and benzoic acids are prepared from benzyl substrates using potassium persulfate as oxidant with catalytic pyridine in acetonitrile under mild conditions. Neither transition metals nor halogens are involved in the reactions.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

Preparation of different amides via Ritter reaction from alcohols and nitriles in the presence of silica-bonded N-propyl sulphamic acid (SBNPSA) under solvent-free conditions

A number of methods have been proposed for the modification of the Ritter reaction. However, many of these methods involve the use of strongly acidic conditions, stoichiometric amounts of reagents, harsh reaction conditions and extended reaction times. Th

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.